Clene Inc美股招股说明书(2025-09-12版)

Up to 491,496 shares of common stock may be offered by Selling Securityholders, including Kensington Clene 2024 LLC, 4Life Research, LLC, and La Scala Investments, LLC, upon the conversion of 2024 Convertible Interest and 2025 SSCP Notes. The offering is part of a shelf registration process and does not guarantee the sale of any shares. Clene Inc. will not receive proceeds from the sale but will cover associated costs. The company is a clinical-stage pharmaceutical firm developing CSN® therapeutics for neurodegenerative diseases like ALS, MS, and PD. Key clinical trials include HEALEY ALS Platform Trial and REPAIR-MS. Clene Inc. faces significant financial challenges, including substantial losses and negative cash flows, and relies on additional funding. The company's ability to continue as a going concern is uncertain.